Differentiation of hematopoietic stem cells into B lymphocytes requires the concerted action of specific transcription factors, such as RUNX1, IKZF1, E2A, EBF1 and PAX5. As key determinants of normal B-cell development, B-lineage transcription factors are frequently deregulated in hematological malignancies, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), and affected by either chromosomal translocations, gene deletions or point mutations. However, genetic aberrations in this developmental pathway are generally insufficient to induce BCP-ALL, and often complemented by genetic defects in cytokine receptors and tyrosine kinases (IL-7Ra, CRLF2, JAK2 and c-ABL1), transcriptional cofactors (TBL1XR1, CBP and BTG1), as well as the regulatory pathways that mediate cell-cycle control (pRB and INK4A/B). Here we provide a detailed overview of the genetic pathways that interact with these B-lineage specification factors, and describe how mutations affecting these master regulators together with cooperating lesions drive leukemia development.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common form of cancer in children characterized by a block in lymphoid differentiation, leading to accumulation of immature progenitor cells in the bone marrow, peripheral blood and occasionally the central nervous system. Although ALL cure rates are approaching 90%, it remains the leading cause of cancer-related mortality in children and young adults. The most prevalent form of childhood ALL is B-cell precursor ALL (BCP-ALL), which represents about 85% of the cases, whereas the remaining 15% of the cases involve T-lineage ALL (T-ALL). In BCP-ALL, two variants of aneuploidy, namely hyperdiploidy of more than 50 chromosomes and hypodiploidy, as well as a collection of recurrent chromosomal rearrangements, give rise to distinct genetic subtypes. 1 These rearrangements include commonly affected genes, such as MLL, CRLF2 or c-Myc, fused to a diverse range of different partner genes or regulatory elements, and uniquely defined chromosomal translocations, such as BCR-ABL1, ETV6-RUNX1 and TCF3-PBX1. Some of these genetic subtypes, such as ETV6-RUNX1 and hyperdiploidy, which together include about 50% of the cases, correlate with a favorable outcome, whereas others, like the MLL rearrangements, BCR-ABL1 and hypodiploidy, covering about 13% of the cases, are associated with a poor treatment response. 1 Many of these chromosomal rearrangements constitute 'driver' mutations and can be detected in both diagnosis and relapse samples. However, it is evident from experimental mouse models and through extensive genomic profiling of patient samples that these genetic driver lesions are usually insufficient to induce leukemia and require cooperating events. Both single-nucleotide polymorphism arrays, as well as deep-sequencing of genomes, and transcriptomes have provided important new insights into the different cellular pathways that are commonly affected by recurrent point mutations, focal gene deletions and rearrangements. [2] [3] [4] In general, BCP-ALL harbors gene lesions that affect transcription factors and signaling molecules implicated in lymphoid differentiation, such as IKZF1, RUNX1, TCF3, EBF1, PAX5, VPREB1 and RAG1/RAG2, as well as proteins that control cell survival and proliferation, including ABL1, NRAS/KRAS, JAK2, IL7R and CRLF2 (Table 1) . Mutations in these two common pathways are often combined with genetic defects in transcriptional coregulators, such as TBL1XR1, CREBBP, BTG1 and well-known tumor-suppressor genes involved in regulation of the cell cycle, such as RB1, CDKN2A, CDKN2B and TP53. Surprisingly, however, many of the BCP-ALL genetic subtypes display a rather unique pattern of specific cooperating gene lesions.
In this review, we will focus on the key hematopoietic transcription factors targeted in BCP-ALL, describing their role in normal and malignant hematopoiesis, and summarizing the cooperating gene lesions and the critical transcriptional targets/ pathways that drive leukemia formation. Specifically, we describe in detail the posttranslational modifications and cofactors that are associated with these transcription factors, regulating their activity and protein stability. A more precise understanding of the regulatory pathways that control these transcription factor functions and their cooperating signaling molecules may hold the key to development of novel targeted therapies aimed at specific BCP-ALL subtypes.
RUNX1
One of the most frequently mutated genes in leukemia is RUNX1 (encoding the acute myeloid leukemia (AML) 1 protein), which belongs to the Runt-related family of transcription factors, together with RUNX2 (AML3) and RUNX3 (AML2). The RUNX proteins together with the common core-binding factor-beta (CBFb) make up the heterodimeric CBF transcription factors, which have important roles in hematopoiesis and bone development. The RUNX proteins directly bind DNA via an N-terminal runt homology domain that also mediates heterodimerization with CBFb, which is required for efficient binding to the RUNX consensus site and results in activation or repression of target genes. The human RUNX1 gene generates three alternatively spliced variants, giving rise to RUNX1a, RUNX1b and RUNX1c, each of which possesses the DNA-binding domain (DBD), while RUNX1a lacks the C-terminal transcriptional regulatory domain. RUNX1 can recruit a variety of transcriptional coactivators, such as the lysine acetyltransferases MOZ and p300/CBP, 5, 6 the transcriptional regulator YAP1 and the protein subunits BRG1 and INI1, which are components of the adenosine triphosphate (ATP) dependent SWI/SNF chromatin-remodeling complex. 7 Transcriptional repression by RUNX1 is mediated through direct binding to the histone deacetylases HDAC1 and HDAC3, the histone methyltransferase SUV39H1 and recruitment of the SIN3A and TLE/Groucho corepressor complexes via the C-terminal region. 8, 9 In addition, RUNX1 can interact in a cooperative manner with several tissue-specific transcription factors, such as GATA1, ETS1, MYB, C/EBPa, PU.1 and STAT5, thereby able to modulate the expression of a broad range of transcriptional target genes.
RUNX1 can be modified through phosporylation by the MAP kinases ERK1/2, 10 which results in enhanced transactivation by RUNX1. In addition, cyclin-dependent kinases (CDKs) are able to phosphorylate RUNX1 on multiple sites, thereby regulating different aspects of AML1 function, including its degradation during G 2 /M phase of the cell cycle by the anaphase-promoting complex, 11 and the interaction with HDAC1 and HDAC3. 12 The DNA-binding affinity of RUNX1 is enhanced by p300-mediated acetylation at two lysine residues (K24 and K43 in RUNX1b). 6 In contrast, both DNA-binding and transactivating properties of RUNX1 are abrogated through lysine methylation by SUV39H1, 13 whereas arginine methylation of residues R206 and R210 by protein arginine methyltransferase 1 (PRMT1) disrupts SIN3A-mediated transcriptional repression of RUNX1.
14 RUNX1 function is also modulated by PRMT4/CARM1, which induces R223 methylation and binding of the zinc-finger protein DPF2, resulting in differential target-gene regulation. 15 Furthermore, PRMT5, in complex with its cofactor COPR5, regulates nuclear export of RUNX1 through R142 methylation.
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RUNX1 and CBFb are essential for all lineages of definitive hematopoiesis in mouse fetal liver, including the formation of erythroid cells, granulocytes, macrophages and lymphoid cells. 17, 18 In particular, mouse Runx1 expression is required for the emergence of hematopoietic stem cells (HSCs) from the vascular endothelium in the midgestation embryo ( Figure 1 ). In contrast, conditional gene-targeting experiments have revealed that the Runx1 gene is not essential for the maintenance of adult long-term HSCs during definitive hematopoiesis. Rather, Runx1 deficiency blocks megakaryopoiesis and lymphocyte development, while at the same time expands multipotent and myeloid progenitors in the bone marrow 19 ( Table 2 ). The identification of RUNX1 target genes has provided some insight into its function during hematopoiesis. Runx1 insufficiency suppresses apoptosis and delays cell-cycle progression in the stem/progenitor cell fraction, which is accompanied by altered expression of the antiapoptotic protein Bcl2 and the polycomb ring-finger oncoprotein Bmi1. 20 The PU.1 (Sfpi1) gene is an essential target of RUNX1 expression in all three major hematopoietic lineages. In myeloid and T-lymphoid cell lineages, RUNX1 regulates the Il3, Csf2, Csf1r, Cd4 and Tcrd genes, whereas in B-lineage differentiation, RUNX1 is essential for Ebf1 expression (Figure 2) . 21 Mouse models have demonstrated that both RUNX1 gain-of-function and loss-offunction predisposes to hematological malignancies. Enhanced or deregulated expression of Runx1 due to integration of murine leukemia virus is a recurrent event upon proviral tagging of lymphoma-prone mice, and RUNX1-transgene expression accelerates the onset of B-and T-cell lymphomas of Em-Myc transgenic mice. 22 On the other hand, conditional or chimeric Runx1-deficient mice develop thymic lymphomas, 23, 24 and are predisposed to leukemia development upon retroviral insertional mutagenesis. RUNX1 is required for the emergence of primitive HSCs during embryonic development, whereas ERG is essential for definitive HSC maintenance. IKZF1 expression is necessary for the formation of common lymphoid progenitors (CLPs), and E2A and EBF1 are essential to generate pro-B cells. PAX5 fulfils a critical role in maintaining B-cell identity, and its expression is required to generate functional pre-B cells. LEF1 mainly regulates early B-cell survival signaling and proliferation. In BCP-ALL, most of the genes that are affected by chromosomal rearrangements, focal gene deletions and point mutations in diagnosis and relapse samples can be classified into four different genetic pathways. [1] [2] [3] [4] B-lineage transcription factors in leukemia E Tijchon et al
In humans, deregulation of RUNX1 expression through chromosomal translocations, mono-and bi-allelic deletions, point mutations and gene amplification is observed in multiple hematopoietic malignancies, including AML, ALL, chronic myeloid leukemia and myelodysplastic syndrome. In addition to somatic mutations, germline point mutations in RUNX1 are responsible for an autosomal-dominant platelet disorder with a propensity to develop leukemia (Familial platelet disorder (FPD)-AML). 26 The most prevalent translocations involving the RUNX1 gene located on chromosome 21q22.12 are RUNX1-MTG8 (encoding the AML1-ETO protein), which occurs in about 15% of AML cases, and ETV6-RUNX1 (encoding the TEL-AML1 protein) that represent the most common genetic subtype in pediatric BCP-ALL, present in 25% of the cases. Although the ETV6-RUNX1 translocation is associated with a favorable outcome, intrachromosomal amplification of chromosome 21 leading to RUNX1 gene amplification predicts an increased risk of relapse and is present in about 2% of childhood BCP-ALL cases. 27 The ETV6-RUNX1 translocation arises most often in utero, generating a preleukemic clone that can persist for years before overt leukemia develops, and which requires additional cooperating events. These include deletions in the CDKN2A locus and copy number alterations (CNAs) in genes regulating B-cell differentiation, such as PAX5 (28%) and EBF1 (10%), but not IKZF1. Furthermore, there is a very strong enrichment for cooperating gene deletions in NR3C1, NR3C2, BTG1 and TBL1XR1 (Figure 3a) 3 , which encode components and regulators of nuclear receptors and together are present in B45% of the ETV6-RUNX1 cases. In addition, 70% of the ETV6-RUNX1-positive leukemias harbor focal deletions in the pre-B-cell receptor gene VPREB1. Another characteristic feature of ETV6-RUNX1-positive leukemias is the high frequency of ETV6 deletions affecting the other nontranslocated ETV6 allele in about three quarters of BCP-ALL cases, arguing that loss of TEL function cooperates with ETV6-RUNX1 in leukemogenesis.
The ETV6-RUNX1 fusion protein has retained the N-terminal non-DNA-binding region of TEL containing the oligomerisation pointed domain, as well as the central repression domain, together with all functional domains of RUNX1 (Figure 4a ). The prevailing notion is that ETV6-RUNX1 binds RUNX1 target sequences and acts as a constitutive inhibitor of transcription through recruitment of SIN3A-and NCoR1-containing corepressor complexes by the ETV6 part of this fusion protein. ETV6-RUNX1 has been shown to promote B-cell differentiation and enhance the self-renewal of multipotent and B-cell progenitors in culture, 28, 29 which requires DNA-and CBFb-binding of the runt homology domain of RUNX1. 29 Furthermore, ETV6-RUNX1 interferes with apoptosis through regulation of survivin via the microRNAs miRNA-494 and miRNA-320a. Other specific pathways affected by 
Lef1
þ / À and Lef1 À / À : no spontaneous hematological malignancies Abbreviations: HSC, hematopoietic stem cell; pDC, plasmacytoid dendritic cell; DN, dominant-negative; T-ALL, T-lineage ALL.
B-lineage transcription factors in leukemia E Tijchon et al ETV6-RUNX1 expression include the phosphoinositide 3-kinase/ AKT/mammalian target of rapamycin (mTOR) and TGF-b pathways. 30, 31 An ETV6-RUNX1 knock-in allele or transgenic expression of ETV6-RUNX1 is insufficient to induce leukemia in mice, 32, 33 but may predispose ETV6-RUNX1 mice to carcinogeninduced T-lineage malignancies. 33 Similarly, transplantation of fetal liver-derived progenitor cells expressing ETV6-RUNX1 into lethally irradiated recipient mice yields no leukemia, but confers a selective advantage on hematopoietic repopulation. 28 Hence, future experiments will need to identify the key cooperating events that drive ETV6-RUNX1-induced progenitor B-cell leukemia development. One promising candidate is the tumor-suppressor gene CDKN2A, which has been shown to promote ETV6-RUNX1-induced leukemogenesis in a bone marrow transplantation assay. 34 
ERG
The ERG gene encodes a member of the E-twenty-six (ETS) family of transcription factors, which are characterized by an ETS domain encoding a winged helix-turn-helix structure for DBD and a pointed protein-interaction domain. The ERG gene encodes six different protein isoforms, due to distinct transcriptional start and termination sites, as well as alternative splicing events. The ERG subfamily also includes ETS family members FLI1 and FEV, both of which have been implicated in different forms of cancer. Many ETS proteins are phosphorylated in response to growth-factor stimulation and cellular stress, but the exact residues modified in ERG as well as the responsible kinases remain to be identified and investigated in more detail. By employing high-throughput sequencing of ERG-binding sites in hematopoietic progenitor cells after chromatin immunopreciptation, it has become evident that ERG binds not only to canonical ETS sites but also shows direct and indirect cooperative interactions with other transcriptional regulators, including GATA2, SCL, LYL1, RUNX1, LMO1 and FLI1. 35 The Erg Mld2/Mld2 mouse mutant harboring a loss-of-function Erg allele, which fails to induce target-gene expression, has revealed that ERG fulfills a critical role in sustaining definitive hematopoiesis 36, 37 ( Figure 1 ). During early embryonic hematopoietic development, Erg is not required for the initial hematopoietic lineage specification from the mesoderm, which coincides with the essential function of Runx1 in HSC emergence. However, at the second wave of hematopoietic development, which involves HSC maintenance, ERG is essential to drive expression of Runx1 and Gata2 and to prevent stem cell exhaustion. 37 Erg Mld2/ þ mice show adequate steady-state HSC maintenance, but display defective HSC renewal during stress-induced hematopoiesis, as well as defective megakaryopoiesis and B-cell development in competitive repopulation assays. 38 Retroviral expression of ERG in progenitor cells appears to promote megakaryopoiesis, increase the frequency of myeloid progenitors and induce expansion of T cells, pro-B cells and erythroid cells. Moreover, enforced ERG expression can induce megakaryoblastic leukemia and T-ALL in mice, but not B-lineage leukemia. 39, 40 Deregulation of ERG function is observed both in solid tumors, such as prostate cancer, Ewing's sarcoma and primitive neuroectodermal tumors, and in hematological malignancies. 41 In leukemia, ERG expression can be downregulated through miR196a and miR-196b. The chromosomal translocation FUS-ERG is detected in AML and BCP-ALL, 41, 42 while overexpression of ERG is associated with poor prognosis in T-ALL, cytogenetically normal adult AML and MLL-rearranged childhood AML. ERG has also been implicated in the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in Down syndrome patients, as ERG is located on chromosome 21q22.2. 43 This is supported by a mouse model for Down syndrome-induced myeloproliferation, where the Erg þ /Mld2 allele corrects the hematological features of this malignant disorder. 44 Childhood BCP-ALL is characterized by the presence of ERG point mutations and mono-allelic gene deletions, which are predicted to produce a truncated ERG protein. 3 Recent studies have defined ERG gene deletions as a separate genetic subtype present in childhood ALL (±7%) associated with a unique geneexpression cluster, which correlates with a good treatment outcome, 45, 46 although gain of ERG mutations have been described in relapsed BCP-ALL cases. This gene expression cluster is characterized by a high frequency of NRAS gene mutations. ERG is a transcriptional regulator of the noncanonical WNT11 gene 47 and the serine/threonine protein kinase PIM1, 48 but it remains to be established which gene targets of ERG are critical in BCP-ALL.
IKZF1
Since its discovery as a key regulator of lymphopoiesis, the transcription factor IKZF1 (Ikaros) and its family members, encoded by the genes IKZF1-IKZF5, have been the subject of intense study in the field of immunology. 49 These transcription factors are characterized by an N-terminal conserved zinc-finger domain that mediates DNA binding, and a C-terminal zinc-finger domain required for homo-and/or heterodimerization with IKZF family members. Alternative splicing of the IKZF1 gene can generate 13 different isoforms that vary in the number of N-terminal zinc fingers and often display compromised DNA binding, giving rise to dominant-negative (DN) isoforms. Like the RUNX1 protein, IKZF1 is known to act both as a repressor and as an activator of transcription. IKZF1 represses target genes through recruitment of HDAC-dependent (SIN3A and Mi-2b/NuRD complexes) and HDACindependent (CtIP and CtBP) corepressors. 50 Transcriptional activation by IKZF1 involves interaction with BRG1-containing SWI/SNF chromatin-remodeling complexes, and through transcription elongation via recruitment of the P-TEFb component Cdk9. 50, 51 IKZF1 function can be modified through several posttranslational modifications. Phosphorylation of IKZF1 protein by casein kinase 2 at multiple sites affects DNA binding, localization to pericentromeric heterochromatin and controls degradation via the ubiquitin pathway. 50 Furthermore, SUMOylation of IKZF1 at two lysine residues (K58 and K241) disturbs its function as transcriptional repressor. Postnatally, a reduced number of T-cells differentiate in the thymus, but these T cells display defects in CD4-versus CD8-lineage differentiation and pre-T-cell receptor and T-cell-receptor selection. 55 A more severe phenotype is observed in mice expressing a DN isoform, which lacks a functional DBD but still contains an intact dimerization motif allowing it to homo-or heterodimerize (Ikaros-DN). Ikaros-DN mice display a more than 100-fold reduction in HSC activity and a complete lack of B-cells, T-cells, natural killer cells and all types of DCs. 56 The most severe phenotype has been described for mice with a single amino-acid change (His191Arg) in the third zinc finger of the DBD, called IkarosPlastic, which interferes with the function of all IKZF family members. Mice homozygous for this mutation die between embryonic day E15.5 and E17.5 due to an additional block in erythroid differentiation resulting in severe anemia. 57 In contrast, Ikaros-null þ / À mice show rather normal lymphoid differentiation, and especially the Ikaros-DN þ / À and Ikaros-Plastic þ / À animals are highly susceptible to develop T-cell malignancies. Consistent with these observations, the Ikzf1 gene is frequently subjected to genetic alterations in various types of mouse T-cell lymphomas, including mutations, deletions and inactivating retroviral insertions. The IKZF1 gene, which consists of eight exons, is targeted by point mutations generating frameshift (fs) or missense mutations, as well as mono-allelic deletions affecting a larger portion of the gene (D4-8) without producing a functional protein ('-'), and intragenic deletions (2) generating DN isoforms (D4-6 and D4-7). These DN isoforms lack the DBD that comprises of four zinc fingers, but retain the dimerization domain, which consists of two zinc fingers. (c) The TCF3 gene encoding the E2A protein consists of 19 exons. The chromosomal translocations TCF3-PBX1 and TCF3-HLF retain the transcriptional activation domains (ADs) of E2A, but harbor the DBD of PBX1 and HLF, respectively. The HLH domain of E2A is not present in the oncogenic fusion proteins.
(d) The EBF1 gene, which consists of 16 exons, is exclusively affected by focal gene deletions that cover a large portion of the coding region, including the ATG ('-'), or generate truncated proteins ('-) encoding a part of the DBD, but lack the IPT/TIG and helix-loop-helix-loophelix motif. (e) The PAX5 gene, which consists of 10 exons, is affected by different gene lesions, including missense and frameshift mutations, intragenic deletions often giving rise to truncated proteins that lack the paired domain (PD) required for DNA binding and translocations. These translocations with multiple-partner genes produce oncogenic PAX5 fusion proteins that still harbor the PD domain, but may lack the octapeptide (O) involved in Groucho binding, the homeodomain-like region (H) and TRD, depending on the breakpoint of the translocation.
The essential role of IKZF1 in hematopoiesis is demonstrated by the fact that IKZF1 primes lymphoid development in the HSC by activating transcription of lymphoid-associated transcription factors (Ebf1) and signaling molecules (Flt3 and IL7r) (Figure 2) , while simultaneously suppressing myeloid-associated transcription factors (Sfpi1 and Gfi1). Second, IKZF1 shuts down gene transcription programs in the lymphoid-primed multipotent progenitors that correlate with stemness (for example, Gata2 and Thy1) and multipotency (for example, Gata1). IKZF1 controls expression of Cd3d and Cd8 genes within the T-cell lineage, whereas it directs early B-cell development by the induction of Rag gene expression and IgH rearrangements, allelic exclusion of the Igk locus and negative regulation of the Igll1 and Dntt promoters, thereby terminating pre-BCR signaling. 50 Furthermore, IKZF1 controls pre-B-cell proliferation by decreasing c-Myc expression in these cells. 59 Beyond the pre-B stage, IKZF1 controls the function of B cells at later stages of development by increasing the activation threshold for mature B cells and regulating the isotype selection during class-switch recombination. 60 Although mouse-knockout models for IKZF1 revealed its potential role as a tumor suppressor, only with the emergence of genome-wide screening methods, IKZF1 was identified as a bona fide leukemia-suppressor gene in childhood ALL. It has now been established that mono-allelic deletions and point mutations of the IKZF1 gene on chromosome 7p12.2 are a common event in childhood ALL and occur in about 10-15% of BCP-ALL and 4% of T-ALL cases 2,3 ( Figure 4b ). These deletions may affect the complete IKZF1 gene, giving rise to haploinsufficiency, or result in intragenic deletions generating DN isoforms due to D 4-6 and D4-7 deletions. Furthermore, single-nucleotide polymorphisms at the IKZF1 gene correlate with an increased risk to develop ALL. 61, 62 Gene deletions and point mutations are also detected in the IKZF3 gene in about 2% of the BCP-ALL cases. 3 Interestingly, IKZF1 deletions are present at a much higher frequency in high-risk BCR-ABL1-positive BCP-ALL (85%), 63 while in chronic myeloid leukemia, IKZF1 deletions are predominantly present in lymphoid blast crises (B20%). In line with these observations, Ikzf1 haploinsufficiency accelerates the onset of B-cell leukemia in p190BCR-ABL1 transgenic mice. 64 IKZF1 gene deletions also frequently occur in another subclass of high-risk childhood leukemia patients, characterized by activating JAK2 point mutations that often harbor high expression of the CRLF2 cytokine receptor as a result of CRLF2 gene rearrangements. 65 A large fraction of the remaining IKZF1-mutated BCP-ALL cases also display a BCR-ABL1-like gene-expression signature, and are often characterized by other variants of ABL1 and JAK2 translocations or gene lesions in IL7R as identified by transcriptome analyses 66 ( Figure 3b) . Notably, deletions and mutations of IKZF1 are associated with a poor clinical outcome and act as a strong predictor of relapse. 67, 68 The pathways downstream of IKZF1 that have a critical role in the onset of BCP-ALL and altered therapy response largely remain to be identified. In mouse T-cell leukemogenesis, aberrant Notchreceptor activation is a critical key event upon loss of IKZF1 function. 69 Whether IKZF1-dependent deregulated expression of Notch or any of its other cancer-related targets, such as CDKinhibitor p27
Kip1 (CDKN1B), 70 c-Myc 59 or phospho-STAT5, 71 contribute to the pathogenesis of BCP-ALL is still an open question. There is compelling evidence that disruption of p19 ARF (CDKN2A gene) is a strong cooperating event together with IKZF1 gene alterations in Ph þ -ALL, and both represent the predominant complementation groups in the BCR-ABL1 subtype of BCP-ALL. 3, 63 However, in these leukemia samples, there is still selection for the presence of additional genetic aberrations in other transcription factors in about 60% of the cases, including PAX5, EBF1 and ETV6, arguing that mono-allelic IKZF1 gene deletions are not sufficient to block B-lymphoid differentiation and probably regulate the additional signaling pathways.
E-BOX-BINDING PROTEINS
Transcriptional regulators of the E-box-binding protein family have important roles in neuronal, muscle cell and lymphoid differentiation. E proteins E12 and E47, generated through alternative splicing of the E2A (TCF3) gene, constitute the class I helix-loop-helix (HLH) transcription factors, together with E2-2 (TCF4) and HEB (TCF12). These HLH transcription factors are characterized by a basic region that mediates DNA binding to the E-box-recognition site, and a HLH domain essential for dimerization. E proteins also share two N-terminal transcriptional activation domains, AD1 and AD2, where the AD1 domain modulates transcription through recruitment of lysine acetyltransferases CBP/ p300 and p/CAF, the Spt-Ada-Gcn5-acetyltransferase (SAGA) complex and members of the ETO family. [72] [73] [74] The DNA-binding activity of E proteins is abrogated upon binding to members of the class IV HLH proteins comprising ID1-ID4, which contain the HLH dimerization motif, but lack a functional DBD. Within the hematopoietic compartment, the E2A proteins form heterodimers with the basic-HLH protein SCL, an essential regulator of hematopoietic development. Proteomic studies have revealed that E47 also interacts with lysine demethylase LSD1, corepressor CoREST and members of the 14-3-3 scaffolding proteins. 75 Furthermore, HEB and E2A bind in a cooperative manner to SMAD2 and SMAD3 transcription factors, effectors of TGFb signaling. E12 and E47 are degraded by the ubiquitinproteasome system through binding to ubiquitin-conjugating enzyme mUbc9 and via Notch-induced association with E3 ubiquitin ligase SCF SKP2 . E2A function is regulated through lysine acetylation by p300/CBP on residue K34 within the AD1 domain, which potentiates transcriptional activation. 74 Phosphorylation of E12/47 by p38-MAPK interferes with transcription activation, 76 while phosphorylation on residues S514 and S529 by CKII and protein kinase A inhibits E47 homodimerization. 77 In addition, human E47 harbors an AKT phosphorylation site (S529), 75 but the functional implication remains to be established.
The Tcfe2a/Tcf3 gene is required to maintain the HSC pool under stress conditions and to promote the development of lymphoid-primed multipotent progenitors, common lymphoid progenitors, early thymocyte progenitors (ETPs), pre-pro-B cells and all subsequent stages of B-cell differentiation. 78, 79 A partial block at the earliest stages of T-cell differentiation in Tcfe2a À / À mice precedes the development of T-cell lymphomas in these mice. 80 E2A directs B-cell fate determination by activating Foxo1 gene expression, which, together with E2A, PU.1 and IL-7R-activated STAT5, induce Ebf1 expression. At the same time, E2A represses myeloid/erythroid-lineage-specifying genes, including Gata1, Csf1r and EpoR. E47 homodimers are the major E proteins in pro-B lymphocytes, consistent with the specific requirement for E2A proteins at this stage of B-cell differentiation. HEB-and E2-2-deficient lymphocytes develop normally, showing a mild reduction in the number of pro-B cells. 81, 82 Compound heterozygous Tcf4 þ / À ;Tcf12 þ / À and Tcf4 þ / À ; Tcfe2a þ / À mice show a more severe phenotype compared with the singleknockout animals, arguing that total level of E proteins, rather than the activity of a specific E-box-binding protein, is important for B-cell development. 81 In contrast, E2-2 fulfills a unique and essential role in the development of plasmacytoid dendritic cells. 83 In addition to Ebf1, other E-protein targets important for B-lymphoid differentiation include Rag1, Rag2, Dntt, Igll1, Vpreb1 and CD79a, as well as V H -DJ H recombination at the IgH locus and Igk rearrangements. Additionally, E2A contributes to activate expression of the Pax5 locus in concerted action with EBF1, FOXO1, IRF4 and IRF8. 84 In peripheral activated B cells, E47 functions to induce Aicda expression and immunoglobulin classswitch recombination, 85 whereas E2-2 influences follicular versus marginal-zone fate determination. 82 The human E-protein-encoding genes TCF3, TCF4 and TCF12 are implicated in several different types of hematological
chromosome 18q21.1) and TCF12 (chromosome 15q21.3) occur at low frequency in pediatric BCP-ALL.
2,4 TCF3 lossof-function genetic alterations on chromosome 19p13.3 include heterozygous gene deletions, which are found in about 70% of the patients suffering from Sezary syndrome, a cutaneous subtype of T-cell lymphomas. 86 At much lower frequencies, chromosomal translocations TCF3-HLF (1%) and TCF3-PBX1 (5%) are found in childhood BCP-ALL (Figure 4c) , both of which are associated with a poor treatment outcome. These oncogenic fusion proteins combine the transcriptional activation domains of E2A with the DBDs of HLF and PBX1, respectively. Both TCF3-HLF and TCF3-PBX1 are thought to interfere with normal E-box-binding/HLH protein function through recruitment of transcriptional coactivators via the AD1 domain of E2A to PBX1 and HLF target genes. Notably, inhibition of E2A/HEB function is an important mechanism for the frequently occurring gain-of-function alterations in HLH protein-encoding genes TAL1/SCL and LYL1 in T-ALL. In general, TCF3-PBX1-positive leukemias display a rather limited amount of cooperating gene deletions, including PAX5 (40%) and CDKN2A (35%). 3 These leukemias are also characterized by almost an obligatory deletion of the other nontranslocated TCF3 allele (95%). TCF3-PBX1 is a regulator of BMI1 expression, thereby alleviating part of the requirement for CDKN2A gene deletions in BCP-ALL.
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TCF3-PBX1 induces the expression of Wnt16, which may affect survival signaling and N-cadherin-dependent adhesion. 88, 89 Experimental mouse models for TCF3-PBX1-induced leukemia show collaboration with Hox gene overexpression in lymphoid malignancies. 90 The oncogenic fusion protein TCF3-HLF suppresses Runx1 transcription and activates expression of Lmo2 and several Groucho-related genes, as well as anti-apoptotic genes Slug and Bcl2. [91] [92] [93] Furthermore, TCF3-HLF mediates overexpression of adenosine triphosphate-dependent drug transporter ABCB1 (MDR1), 94 which may contribute to the poor treatment outcome of leukemias harboring a TCF3-HLF translocation. Thus, TCF3-PBX1 and TCF3-HLF seem to regulate different target genes, but may employ similar mechanisms of ectopic recruitment of transcriptional coactivators, like CBP/p300 and components of the SAGA complex, which are important for the oncogenic properties of these leukemia-associated fusion proteins.
EBF1
The early B-cell factor (EBF) transcription factors EBF1-EBF4 have an important role in the development of a number of specialized cell types, including neurons, adipocytes and lymphocytes. EBF proteins are composed of a highly conserved N-terminal DBD, an IPT/TIG (immunoglobulin, plexins, transcription factors-like/transcription factor immunoglobulin) domain, an atypical helix-loophelix-loop-helix (HLHLH) motif and a less conserved C-terminal domain, which contributes to transcriptional activation. EBF proteins bind DNA as homo-or heterodimers via a unique motif specific for the EBF family, termed the 'zinc knuckle' located within the DBD. 95, 96 EBF1 interacts with transcriptional coactivator CBP, but surprisingly inhibits its lysine acetyltransferase activity. 97 Two related large zinc-finger proteins, ZFP423 and ZFP521, can bind EBF1 and are capable of recruiting Mi-2b/NuRD complexes. Gene silencing of Mi-2b subunit seems to potentiate EBF1-mediated gene activation. 98 Furthermore, EBF1 inhibits DNA methylation of specific target genes (for example, Cd79a), which is counteracted by Mi-2b/NuRD. On the other hand, EBF1 requires the BRG1-and BRM-containing SWI/SNF complex to activate target genes. 98 The essential role of EBF1 in B-cell lineage commitment has become evident from various mouse studies. Mice deficient for Ebf1 show an absolute block in differentiation at the pre-pro-B-cell stage. 99 Forced expression of EBF1 in E2A-deficient cells rescues B-cell differentiation, arguing that EBF1 acts downstream of E2A in B-cell development. 100 EBF1 is essential for the rearrangement of
IgH and IgL loci and expression of genes essential for B-lineage specification and commitment, including Cd79a, Cd79b, Vpreb1, Igll1, Foxo1 and Pax5. EBF1 and PAX5 positively cross-regulate each other's promoters at early stages of B-cell development, thereby providing an auto-regulatory loop critically important for B-cell specification. EBF1 antagonizes the expression of Cebpa, Sfpi1, Id2, Id3 and several natural-killer-cell-specific genes. 101, 102 EBF1 also appears to be a critical regulator of proliferative expansion and survival of pro-B cells by activating expression of c-Myb and controlling Akt and canonical B-cell receptor (BCR) signaling. 103 Genome-wide chromatin immunopreciptation analyses have revealed the identification of several new EBF1 target genes, including Hlx, Ctla4 and Gfi1b.
104 Ectopic EBF1 expression in hematopoietic progenitor cells forces B-cell development at the expense of myeloid cell fates. 101, 105 At later stages of B-cell differentiation, EBF1 is essential for the development of B1 and marginal-zone B cells, and maintenance of follicular and germinal center B cells. 103, 106 Ebf1 þ / À mice display a 50% decrease in pro-B cells and a 10-30% reduction in splenic B cells, but are not prone to develop spontaneous leukemia. However, combining a constitutive active transgenic STAT5 allele with Ebf1 haploinsufficiency yields progenitor B-cell leukemias with a penetrance of 100%. 107 In human ALL, mono-allelic deletions affecting the EBF1 gene on chromosome 5q33.3 have been reported in a small fraction of the total BCP-ALL cohort (4%). 3 These deletions are variable in size, but frequently affect a large portion of the EBF1 open-reading frame, suggesting a loss-of-function phenotype (Figure 4d ). Genetic aberrations affecting EBF1 are more prevalent in highrisk leukemia patients, including BCR-ABL1-positive cases (14%) and in a novel defined cluster (38%) characterized by a high frequency of TP53/RB1 and JAK mutations, together with other B-cell pathway gene deletions. 45 Notably, EBF1 haploinsufficiency occurs more frequently in combination with BTG1 gene deletions (26%), suggesting that these tumor-suppressor genes may cooperate in leukemogenesis.
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PAX5
The guardian of B-cell identity PAX5, also known as B-cell specific activator protein, is one of the nine PAX transcription factors, but the only one expressed within the hematopoietic system. A characteristic feature of PAX protein family is the conserved paired domain, which functions as a bipartite DNA-binding region and consist of an N-and C-terminal subdomain. Each subdomain binds to a distinct half-site of a degenerate consensus recognition sequence. PAX5 displays cooperative DNA binding with other transcription factors, such as MYB and ETS1, and has been shown to repress PU.1 transactivation through direct binding. 109 Besides the paired domain, PAX5 harbors two interaction domains for Groucho corepressors, 110 a partial homeodomain that serves as a binding domain for pRb, 111 and a potent C-terminal transactivation domain that interacts with the SAGA complex and lysine acetyltransferases CBP/p300, which induce lysine acetylation of the PAX5 DBD. 112 Alternative splicing of the Pax5 gene generates multiple protein isoforms that differ in the C-terminal transactivation domain, but their individual functions remain to be established. The death-domain-associated protein DAXX has been shown to bind PAX5, thereby modulating its transcriptional activity. 113 Proteomic studies have demonstrated that PAX5 can also recruit the TBP, TAF4 and TAF6 subunits of the basal transcription factor complex TFIID, the SWI/SNF chromatin-remodeling components BRG1, BAF57 and BAF170, the RbBP5 subunit of the MLL-containing H3K4 methyltransferase complex and corepressor NCoR1. 114 Thus, PAX5 is able to regulate target genes through its interplay with different epigenetic modifiers in a context-dependent manner.
During B lymphopoiesis, Pax5 expression starts at the pro-B cell stage acting downstream of E2A and EBF1 in the B-cell differentiation pathway, and its levels are maintained until plasma cell differentiation occurs. At the early stages of B-cell development, the Pax5 gene is subjected to allele-specific regulation, with only one allele being transcribed, whereas it switches to bi-allelic expression in immature B cells. 115 During the initial phase of fetal hematopoiesis, Pax5 deficiency results in a block before the appearance of B220 þ progenitors, while in adult Pax5-deficient mice, B-cell development proceeds until the c-Kit þ B220 þ pro-B cell stage. 116, 117 Specifically, Pax5-deficient bone marrow cells are halted at the stage of V H -to-DJ H rearrangement. However, Pax5
À / À pro-B cells are not yet fully committed to the B-cell lineage, because these cells remain pluripotent and are able to differentiate into functional macrophages, granulocytes, dendritic cells, osteoclasts and natural killer cells in the presence of the appropriate cytokines. 118 Enforced expression of PAX5 in multipotent progenitors results in the production of biphenotypic myeloid/B-lymphoid cells with extensive self-renewal capacity.
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PAX5 fulfills a dual role as master regulator of lineage commitment by repressing non-B-lineage genes (Notch1, Csf1r, Csf1 and CD28) and differentiation-stage inappropriate genes (Flt3, Sca1 and Blimp1), while activating (pro-) B-cell-specific genes, including components of receptor signaling (Cd79a, Cd19, Blnk, Cd72 and Igk) and genes encoding transcriptional regulators (Ebf1, Lef1, Tcf4, Ikzf3, Id3, Bach2, Irf4 and Irf8). In addition, PAX5 permits accessibility of the immunoglobulin heavy chain locus through binding to PAX5-activated intergenic repeat elements.
120 PAX5 expression is enhanced in activated B cells and essential for classswitch recombination, by activating Aid expression. However, PAX5-target genes in early and late B lymphopoiesis appear to be quite distinct.
121 PAX5 remains required for maintaining the B-cell gene-expression program, as conditional Pax5 gene inactivation results in the conversion of mature B cells into functional T cells by dedifferentiation to uncommitted progenitors in the bone marrow. 122, 123 In addition, complete loss of PAX5 in mature B cells leads to the development of aggressive progenitor B-cell lymphomas in these mice. 123 In vivo studies have shown that constitutive active STAT5 expression in combination with Pax5 haploinsufficiency drive ALL development. 107 On the other hand, ectopic PAX5 expression in the T-cell lineage induces immature lymphoblastic T-cell lymphomas in IgH-PAX5 transgenic mice.
The PAX5 gene located on chromosome 9p13.2 is deregulated in a small fraction of diffuse large B-cell lymphomas, which results from translocations involving the IgH enhancer (Em) and correlate with elevated PAX5 levels. 124 In addition, aberrant ectopic expression of PAX5 has been reported in AML. 125 On the other hand, PAX5 loss-of-function genetic lesions have been identified in a high percentage of childhood and adult BCP-ALL cases ( ± 35%), which include predominantly mono-allelic deletions that sometimes involves a larger segment of chromosome 9p and point mutations, as well as some chromosomal translocations generating a large variety of distinct chimeric PAX5 fusion proteins (Figure 4e ). PAX5 mutations have also been identified in splenic marginal-zone lymphomas and diffuse large B-cell lymphomas. 126 Recurrent translocations in BCP-ALL include PAX5-ETV6, PAX5-C20orf112, PAX5-FOXP1 and PAX5-PML that predominantly act to suppress PAX5-target genes.
3,127 PAX5 CNAs are detected in virtually all BCP-ALL genetic subtypes, but occur more frequently in BCR-ABL1-(50%) and TCF3-PBX1-positive cases (41%). 3, 128 The frequent concurrent deletion of PAX5 and CDKN2A suggests that they are cooperating events in the pathogenesis of BCP-ALL. 3, 129 There is no significant association between clinical outcome and PAX5 status, despite the finding that PAX5 is commonly mutated in ALL. 67 
LEF1
Deregulation of the canonical Wnt/b-catenin signaling pathway has been identified as a hallmark of multiple cancers, including hematological malignancies. This pathway is activated via ligation of secreted Wnt proteins to their receptors and inhibition of the Ser/Thr kinase GSK-3b. As a consequence, the transcriptional coactivator b-catenin is stabilized, allowing it to translocate to the nucleus and bind to the T-cell factor/lymphoid-enhancer factor transcription factors TCF7, TCF7L1, TCF7L2 and LEF1. This results in a transcriptional switch from repression to activation, through recruitment of coactivator complexes, including BRG1, p300/CBP, the ATAC acetyltransferase complex, BCL9 and the chromatinremodeling factors Pygo1/Pygo2. [130] [131] [132] [133] Another level of complexity is introduced by the expression of distinct isoforms for each of the T-cell factor/lymphoid-enhancer factor family members, where alternative splicing generates four different LEF1 isoforms. Moreover, there is a natural occurring LEF1-antisense transcript located at the 5 0 end of the gene, which has not yet been studied in great detail. LEF1 contains a DBD that shows homology to members of the high-mobility group proteins, and binds DNA as a monomer inducing a sharp bend in the DNA. In the absence of Wnt signaling, LEF1 predominantly acts as a transcriptional repressor by assembling CtBP, TLE/Groucho and HDAC molecules to its target genes. 133 The Wnt/b-catenin signaling pathway controls the proliferation, survival and differentiation of hematopoietic cells. Self-renewal of HSCs coincides with activation of the b-catenin pathway, and high levels of constitutively activated b-catenin in HSCs confer myeloid potential on lymphoid progenitors. 134 Mice deficient for Lef1 display reduced proliferation and enhanced apoptosis of pro-B cells, but no defect in B-cell differentiation, 135 whereas ectopic LEF1 expression promotes myeloid at the expense of lymphoid development. 136 Moreover, enforced LEF1 expression in bone marrow progenitor cells results in myeloid and lymphoid malignancies upon transplantation into lethally irradiated recipient mice. 136 In human CD34 þ cells, inhibition of LEF1, but not of b-catenin, affects proliferation and apoptosis of these cells, suggesting that LEF1 may fulfill b-catenin-independent functions in early human progenitor cells. 137 Furthermore, these studies have demonstrated a role of LEF1 in neutrophil differentiation, which correlates with regulation of the ELA2 gene by LEF1 together with CBFa.
Enhanced activation and strong nuclear localization of b-catenin has been demonstrated in chronic myeloid leukemia, ALL, AML, mantle cell and cutaneous lymphoma. The one way this pathway can be modulated is through epigenetic gene silencing of Wnt antagonists, as observed in AML and ALL. 138, 139 In addition, overexpression of LEF1 has been observed in CLL, ALL, AML and lymphomas and associated with enhanced survival properties of CLL cells and poor treatment outcome in adult BCP-ALL patients. 140, 141 On the other hand, recurrent inactivating monoallelic and bi-allelic microdeletions, and truncating point mutations of the LEF1 gene, located on chromosome 4q25, have been reported in pediatric T-ALL (17%) and BCP-ALL (2%). 3, 142 Somatic mutations in TCF7L2 have also been described in BCP-ALL. 143 Deficiency for LEF1 function has been linked to enhanced c-MYC and FAS expression, 135, 142 but whether these LEF1-target genes critically contribute to human leukemogenesis remains to be determined.
CONCLUDING REMARKS
Genomic profiling by single-nucleotide polymorphism arrays and genomic sequencing have led to the identification and characterization of novel genetic lesions that not only contribute to the pathogenesis of BCP-ALL, but in some cases also predict therapy response. It is evident that the B-lineage transcription factors described in this review have a central role in the differentiation and survival of lymphocyte progenitor cells. However, for many of these factors, it remains to be established how they contribute to leukemia development or which cooperating events are required to develop the disease. In addition, the observation that both gain-of-function and loss-of-function genetic lesions that affect proteins, such as AML1, ERG, PAX5 and LEF1, may contribute the oncogenic transformation of hematopoietic cells, calls for a more detailed understanding of the distinct signals regulated by these transcription factors. Extensive network structure analyses will provide additional insight into the key target genes that are regulated by these mutated transcription factors. 144 The next step will be to translate this knowledge into improved therapy modalities for the patient. These may include drugs that interfere with the action of epigenetic regulators recruited by oncogenic fusion proteins, such as ETV6-RUNX1 and TCF3-PBX1. It can be expected that such developments will lead the way from standard (chemo-)therapy to personalized medicine for patients with BCP-ALL.
